Author:
- INTRODUCTION
- MATERIALS AND METHODS
- Perspective and boundary.
- Model overview.
- Alternatives being compared.
- Measuring health gains.
- Assumptions on vaccine efficacy.
- Coverage.
- Case management.
- Costs presented.
- Vaccine delivery costs.
- Case management costs.
- Measuring productivity gains.
- Net cost calculations.
- Reference scenario.
- Sensitivity analysis.
- RESULTS
- DISCUSSION
ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1
Drummond MB, O’Brien B, Stoddart GL, Torrance G, 1997. Methods for the Economic Evaluation of Health Care Programmes. Second edition. Oxford, United Kingdom: Oxford University Press.
-
2
Gold MR, Gold SR, Weinstein MC, 1996. Cost-Effectiveness in Health and Medicine. Oxford, United Kingdom: Oxford University Press.
-
3
Tediosi F, Maire N, Smith T, Hutton G, Utzinger J, Ross A, Tanner M, 2006. An approach to model the costs and effects of case management of Plasmodium falciparum malaria in sub-Saharan Africa. Am J Trop Med Hyg 75 (Suppl 2):90–103.
-
4
Tediosi F, Hutton G, 2006. The costs of introducing a malaria vaccine through the expanded program on immunization in Tanzania. Am J Trop Med Hyg 75 (Suppl 2):119–130.
-
5
Maire N, Tediosi F, Ross A, Smith T, 2006. Predicting the epidemiologic impact of introducing a pre-erythrocytic malaria vaccine into the expanded program on immunization schedule in sub-Saharan Africa. Am J Trop Med Hyg 75 (Suppl 2):111–118.
-
6
Smith T, Killeen G, Maire N, Ross A, Molineaux L, Tediosi F, Hutton G, Utzinger J, Dietz K, Tanner M, 2006. Mathematical modeling of the impact of malaria vaccines on the clinical epidemiology and natural history of Plasmodium falciparum malaria: overview. Am J Trop Med Hyg 75 (Suppl 2):1–10.
-
7
Hall AJ, Robertson RL, Crivelli PE, Lowe Y, Inskip H, Snow SK, Whittle H, 1993. Cost-effectiveness of hepatitis B vaccine in The Gambia. Trans R Soc Trop Med Hyg 87 :333–336.
-
8
Edmunds WJ, Dejene A, Mekonnen Y, Haile M, Alemnu W, Nokes DJ, 2000. The cost of integrating hepatitis B virus vaccine into national immunization programmes: a case study from Addis Ababa. Health Policy Plann 15 :408–416.
-
9
Griffiths U, Hutton G, das Dores Pascoal E, 2005. Cost-effectiveness of introducing hepatitis B vaccine into the infant immunization schedule in Mozambique. Health Policy Plann 20 :50–59.
-
10
Maire N, Aponte J, Ross A, Thompson R, Utzinger J, Smith T, 2006. Modeling a field trial of the RTS,S/ASO2A malaria vaccine. Am J Trop Med Hyg 75 (Suppl 2):104–110.
-
11
Smith T, Charlwood JD, Kihonda J, Mwankusye S, Billingsley P, Meuwissen J, Lyimo E, Takken W, Teuscher T, Tanner M, 1993. Absence of seasonal variation in malaria parasitaemia in an area of intense seasonal transmission. Acta Trop 54 :55–72.
-
12
Hay SI, Rogers DJ, Toomer JF, Snow R, 2000. Annual Plasmodium falciparum entomological inoculation rates (EIR) across Africa: literature survey, Internet access and review. Trans R Soc Trop Med Hyg 94 :113–127.
-
13
INDEPTH Network, 2002. Population, Health and Survival at INDEPTH Sites. Ottawa, Ontario, Canada: International Development Research Centre.
-
14
Murray CJ, Lopez AD, 1996. Estimating causes of death: new methods and global and regional applications for 1990. Murray CJ, Lopez AD, eds. The Global Burden of Disease. Geneva: World Health Organization.
-
15
Murray CJ, Lopez AD, 1996. The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability from Diseases, Injuries, and Risk Factors in 1990 and Projected to 2020. Cambridge, MA: Harvard University Press.
-
16
INDEPTH Network, 2004. Model Life Tables for Sub-Saharan Africa. Aldershot, United Kingdom: Ashgate.
-
17
Chima RI, Goodman CA, Mills A, 2003. The economic impact of malaria in Africa: a critical review of the evidence. Health Policy 63 :17–36.
-
18
Tan-Torres Edejer T, Baltussen R, Adam T, Hutubessy R, Acharya A, Evans D, Murray C, 2003. Making Choices in Health: WHO Guide to Cost-Effectiveness Analysis. Geneva: World Health Organization.
-
19
Goodman CA, Coleman PG, Mills A, 1999. Cost-effectiveness of malaria control in sub-Saharan Africa. Lancet 354 :378–385.
-
20
Goodman C, Coleman P, Mills A, 2000. Economic Analysis of Malaria Control in Sub-Saharan Africa. Geneva: Global Forum for Health Research.
-
21
Weinstein M, Siegel J, Gold M, Kamlet M, Russell L, 1996. Recommendations of the panel of cost-effectiveness in medicine. JAMA 276 :1253–1341.
-
22
Shepard DS, Ettling MB, Brinkmann U, Sauerborn R, 1991. The economic cost of malaria in Africa. Trop Med Parasitol 42 :199–203.
-
23
Sachs J, Malaney P, 2002. The economic and social burden of malaria. Nature 415 :680–685.
-
24
Malaney P, Spielman A, Sachs J, 2004. The malaria gap. Am J Trop Med Hyg 71 (Suppl 2):141–146.
-
25
Sachs JD, 2001. Macroeconomics and Health: Investing in Health for Economic Development. Geneva: World Health Organization, Commission on Macroeconomics and Health.
-
26
Marsh K, Snow R, 1999. Malaria transmission and morbidity. Parassitologia 41 :241–246.
-
27
Ross A, Maire N, Molineaux L, Smith T, 2006. An epidemiologic model of severe morbidity and mortality caused by Plasmodium falciparum. Am J Trop Med Hyg 75 (Suppl 2):63–73.
-
28
Smith T, Ross A, Maire N, Rogier C, Trape JF, Molineaux L, 2006. An epidemiologic model of the incidence of acute illness in Plasmodium falciparum malaria. Am J Trop Med Hyg 75 (Suppl 2):56–62.
-
29
Trape JF, Rogier C, 1996. Combating malaria morbidity and mortality by reducing transmission. Parasitol Today 12 :236–240.
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 681 | 592 | 133 |
| Full Text Views | 383 | 19 | 2 |
| PDF Downloads | 144 | 19 | 1 |
PREDICTING THE COST-EFFECTIVENESS OF INTRODUCING A PRE-ERYTHROCYTIC MALARIA VACCINE INTO THE EXPANDED PROGRAM ON IMMUNIZATION IN TANZANIA
FABRIZIO TEDIOSI
FABRIZIO TEDIOSI
Swiss Tropical Institute, Basel, Switzerland
Search for other papers by FABRIZIO TEDIOSI in
Current site
Google Scholar
PubMed
Search for other papers by FABRIZIO TEDIOSI in
Current site
Google Scholar
PubMed
GUY HUTTON
GUY HUTTON
Swiss Tropical Institute, Basel, Switzerland
Search for other papers by GUY HUTTON in
Current site
Google Scholar
PubMed
Search for other papers by GUY HUTTON in
Current site
Google Scholar
PubMed
NICOLAS MAIRE
NICOLAS MAIRE
Swiss Tropical Institute, Basel, Switzerland
Search for other papers by NICOLAS MAIRE in
Current site
Google Scholar
PubMed
Search for other papers by NICOLAS MAIRE in
Current site
Google Scholar
PubMed
THOMAS A. SMITH
THOMAS A. SMITH
Swiss Tropical Institute, Basel, Switzerland
Search for other papers by THOMAS A. SMITH in
Current site
Google Scholar
PubMed
Search for other papers by THOMAS A. SMITH in
Current site
Google Scholar
PubMed
AMANDA ROSS
AMANDA ROSS
Swiss Tropical Institute, Basel, Switzerland
Search for other papers by AMANDA ROSS in
Current site
Google Scholar
PubMed
Search for other papers by AMANDA ROSS in
Current site
Google Scholar
PubMed
MARCEL TANNER
MARCEL TANNER
Swiss Tropical Institute, Basel, Switzerland
Search for other papers by MARCEL TANNER in
Current site
Google Scholar
PubMed
Search for other papers by MARCEL TANNER in
Current site
Google Scholar
PubMed
We model the cost-effectiveness of the introduction of a pre-erythrocytic malaria vaccine into the Expanded Program on Immunization. We use a dynamic stochastic simulation model of the epidemiology of Plasmodium falciparum in malaria-endemic areas and of case management in Tanzania. We consider a range of vaccine characteristics and a range of transmission settings. At low vaccine prices, the cost-effectiveness of such vaccines may be similar to that of other established preventative and curative interventions against malaria. The cost-effectiveness ratio increases rapidly and approximately linearly with vaccine cost per dose. The approach can be adopted for comparative analyses of the cost effectiveness of different vaccines and other intervention strategies.
Author Notes
- INTRODUCTION
- MATERIALS AND METHODS
- Perspective and boundary.
- Model overview.
- Alternatives being compared.
- Measuring health gains.
- Assumptions on vaccine efficacy.
- Coverage.
- Case management.
- Costs presented.
- Vaccine delivery costs.
- Case management costs.
- Measuring productivity gains.
- Net cost calculations.
- Reference scenario.
- Sensitivity analysis.
- RESULTS
- DISCUSSION
ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1
Drummond MB, O’Brien B, Stoddart GL, Torrance G, 1997. Methods for the Economic Evaluation of Health Care Programmes. Second edition. Oxford, United Kingdom: Oxford University Press.
-
2
Gold MR, Gold SR, Weinstein MC, 1996. Cost-Effectiveness in Health and Medicine. Oxford, United Kingdom: Oxford University Press.
-
3
Tediosi F, Maire N, Smith T, Hutton G, Utzinger J, Ross A, Tanner M, 2006. An approach to model the costs and effects of case management of Plasmodium falciparum malaria in sub-Saharan Africa. Am J Trop Med Hyg 75 (Suppl 2):90–103.
-
4
Tediosi F, Hutton G, 2006. The costs of introducing a malaria vaccine through the expanded program on immunization in Tanzania. Am J Trop Med Hyg 75 (Suppl 2):119–130.
-
5
Maire N, Tediosi F, Ross A, Smith T, 2006. Predicting the epidemiologic impact of introducing a pre-erythrocytic malaria vaccine into the expanded program on immunization schedule in sub-Saharan Africa. Am J Trop Med Hyg 75 (Suppl 2):111–118.
-
6
Smith T, Killeen G, Maire N, Ross A, Molineaux L, Tediosi F, Hutton G, Utzinger J, Dietz K, Tanner M, 2006. Mathematical modeling of the impact of malaria vaccines on the clinical epidemiology and natural history of Plasmodium falciparum malaria: overview. Am J Trop Med Hyg 75 (Suppl 2):1–10.
-
7
Hall AJ, Robertson RL, Crivelli PE, Lowe Y, Inskip H, Snow SK, Whittle H, 1993. Cost-effectiveness of hepatitis B vaccine in The Gambia. Trans R Soc Trop Med Hyg 87 :333–336.
-
8
Edmunds WJ, Dejene A, Mekonnen Y, Haile M, Alemnu W, Nokes DJ, 2000. The cost of integrating hepatitis B virus vaccine into national immunization programmes: a case study from Addis Ababa. Health Policy Plann 15 :408–416.
-
9
Griffiths U, Hutton G, das Dores Pascoal E, 2005. Cost-effectiveness of introducing hepatitis B vaccine into the infant immunization schedule in Mozambique. Health Policy Plann 20 :50–59.
-
10
Maire N, Aponte J, Ross A, Thompson R, Utzinger J, Smith T, 2006. Modeling a field trial of the RTS,S/ASO2A malaria vaccine. Am J Trop Med Hyg 75 (Suppl 2):104–110.
-
11
Smith T, Charlwood JD, Kihonda J, Mwankusye S, Billingsley P, Meuwissen J, Lyimo E, Takken W, Teuscher T, Tanner M, 1993. Absence of seasonal variation in malaria parasitaemia in an area of intense seasonal transmission. Acta Trop 54 :55–72.
-
12
Hay SI, Rogers DJ, Toomer JF, Snow R, 2000. Annual Plasmodium falciparum entomological inoculation rates (EIR) across Africa: literature survey, Internet access and review. Trans R Soc Trop Med Hyg 94 :113–127.
-
13
INDEPTH Network, 2002. Population, Health and Survival at INDEPTH Sites. Ottawa, Ontario, Canada: International Development Research Centre.
-
14
Murray CJ, Lopez AD, 1996. Estimating causes of death: new methods and global and regional applications for 1990. Murray CJ, Lopez AD, eds. The Global Burden of Disease. Geneva: World Health Organization.
-
15
Murray CJ, Lopez AD, 1996. The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability from Diseases, Injuries, and Risk Factors in 1990 and Projected to 2020. Cambridge, MA: Harvard University Press.
-
16
INDEPTH Network, 2004. Model Life Tables for Sub-Saharan Africa. Aldershot, United Kingdom: Ashgate.
-
17
Chima RI, Goodman CA, Mills A, 2003. The economic impact of malaria in Africa: a critical review of the evidence. Health Policy 63 :17–36.
-
18
Tan-Torres Edejer T, Baltussen R, Adam T, Hutubessy R, Acharya A, Evans D, Murray C, 2003. Making Choices in Health: WHO Guide to Cost-Effectiveness Analysis. Geneva: World Health Organization.
-
19
Goodman CA, Coleman PG, Mills A, 1999. Cost-effectiveness of malaria control in sub-Saharan Africa. Lancet 354 :378–385.
-
20
Goodman C, Coleman P, Mills A, 2000. Economic Analysis of Malaria Control in Sub-Saharan Africa. Geneva: Global Forum for Health Research.
-
21
Weinstein M, Siegel J, Gold M, Kamlet M, Russell L, 1996. Recommendations of the panel of cost-effectiveness in medicine. JAMA 276 :1253–1341.
-
22
Shepard DS, Ettling MB, Brinkmann U, Sauerborn R, 1991. The economic cost of malaria in Africa. Trop Med Parasitol 42 :199–203.
-
23
Sachs J, Malaney P, 2002. The economic and social burden of malaria. Nature 415 :680–685.
-
24
Malaney P, Spielman A, Sachs J, 2004. The malaria gap. Am J Trop Med Hyg 71 (Suppl 2):141–146.
-
25
Sachs JD, 2001. Macroeconomics and Health: Investing in Health for Economic Development. Geneva: World Health Organization, Commission on Macroeconomics and Health.
-
26
Marsh K, Snow R, 1999. Malaria transmission and morbidity. Parassitologia 41 :241–246.
-
27
Ross A, Maire N, Molineaux L, Smith T, 2006. An epidemiologic model of severe morbidity and mortality caused by Plasmodium falciparum. Am J Trop Med Hyg 75 (Suppl 2):63–73.
-
28
Smith T, Ross A, Maire N, Rogier C, Trape JF, Molineaux L, 2006. An epidemiologic model of the incidence of acute illness in Plasmodium falciparum malaria. Am J Trop Med Hyg 75 (Suppl 2):56–62.
-
29
Trape JF, Rogier C, 1996. Combating malaria morbidity and mortality by reducing transmission. Parasitol Today 12 :236–240.
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 681 | 592 | 133 |
| Full Text Views | 383 | 19 | 2 |
| PDF Downloads | 144 | 19 | 1 |